EXHIBIT A AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13GJoint Filing Agreement • June 1st, 2020 • Nostrum Pharmaceuticals, LLC • Biological products, (no disgnostic substances)
The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G (and any amendments or supplements thereto) required under section 13(d) of the Securities Exchange Act of 1934, as amended, in connection with purchases and sales by the undersigned of the securities of Gene Biotherapeutics, Inc. until such time as the undersigned file with the SEC a statement terminating this Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 1st, 2020 • Nostrum Pharmaceuticals, LLC • Biological products, (no disgnostic substances) • New York
THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”) is made and entered into, effective as of May 22, 2020 (the “Effective Date”), by and between sabby healthcare master fund, ltd. (formerly known as Sabby Healthcare Volatility Master Fund, Ltd.), a Cayman Islands exempt company (“Seller”), and NOSTRUM PHARMACEUTICALS LLC, a Delaware limited liability company (“Purchaser”). Capitalized terms that are not defined in the text of this Agreement have the meanings ascribed to such terms in Appendix 1.
